eXoZymes (EXOZ) investor relations material

Company overview and business model

• Develops natural product compounds using proprietary cell-free exozyme technology for efficient production of complex molecules, such as NCT, targeting health supplements and drug discovery markets.

• Cell-free biomanufacturing platform enables scalable, sustainable production of high-value compounds beyond traditional extraction or petrochemical synthesis.

• Focuses on enzyme-based, AI-enhanced pathways operating outside living cells, offering greater control and efficiency.

Financial performance and metrics

• Financial statements for years ended December 31, 2024 and 2023 were audited, with a going concern explanatory paragraph included.

• As of January 16, 2026, 8,400,258 shares of common stock were issued.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes, including capital expenditures, R&D, regulatory affairs, clinical trials, acquisitions, and business expansions.

• Management retains broad discretion over allocation of proceeds, which may vary based on development progress and unforeseen needs.